Magnesium sulfate administration

ApprovedSmall molecule

UUniversity of California, San Francisco

Magnesium sulfate administration is one of 39 small molecule programs targeting Severe Pre-Eclampsia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Pre-EclampsiaActive, not recruiting

Atrial FibrillationActive, not recruiting

Severe Pre-EclampsiaPreclinical

Active, not recruiting

Atrial FibrillationApproved

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Magnesium sulfate administration

UUniversity of California, San Francisco

Approved

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Imbruvica

PPharmacyclics LLC.

Preclinical

1 8

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Atrial Fibrillation

NCT07173855

Clinical

Trials by Indication[1]

Severe Pre-Eclampsia1 trial

Serum Magnesium Level Administration in Severe Pre-eclampsia Obese Pregnancy

Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·N/A·NCT03661775·60 enrolled

Atrial Fibrillation1 trial

Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

Recruiting·SScarborough General Hospital·Phase 4·NCT07173855·3,253 enrolled

Unspecified1 trial

Effect of Magnesium on Neuromonitoring

Recruiting·UUniversity of California, San Francisco·Phase 4·NCT06975072·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Magnesium sulfate administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Magnesium sulfate administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Magnesium sulfate administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of California, San Francisco

Magnesium sulfate administration

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Severe Pre-Eclampsia1 trial

Atrial Fibrillation1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News